AwesomeCapital

Alnylam books $38M in Onpattro sales in Q2

Alnylam Pharmaceuticals (NASDAQ:ALNY) Q2 results: Revenues: $44.7M (+49%). Onpattro sales: $38.2M.

Net loss: ($219.5M); loss/share: ($2.02).

Data readouts from pivotal studies of inclisiran and lumasiran expected in H2. Phase 3s to be initiated: APOLLO-B (patisiran) in ATTR amyloidosis with cardiomyopathy, HELIOS-B (vutrisiran) in ATTR amyloidosis with cardiomyopathy and ILLUMINATE-C (lumasiran) in PH1 with severe renal impairment.

Shares are down 5% premarket on light volume.

Previously: Alnylam Pharmaceuticals EPS beats by $0.33, beats on revenue(Aug. 6)

https://seekingalpha.com/news/3487466-alnylam-books-38m-onpattro-sales-q2

Can-Fite to supply Namodensoson in Israel under compassionate use

Can-Fite BioPharma (NYSEMKT:CANF) announces that is has manufactured a supply of Namodenoson for Israeli liver cancer patients under compassionate use at the Rabin Medical Center in Petah Tikva.

Compassionate use allows access to investigational drugs for patients with no other viable treatment options.

Shares are up 6% premarket on light volume.

https://seekingalpha.com/news/3487488-can-fite-supply-namodensoson-israel-compassionate-use-shares-6-percent-premarket

Care.com EPS beats by $0.01, misses on revenue

Care.com (NYSE:CRCM): Q2 Non-GAAP EPS of $0.09 beats by $0.01; GAAP EPS of -$2.01 misses by $1.95.

Revenue of $50.98M (+10.9% Y/Y) misses by $1.22M.

Press Release

https://seekingalpha.com/news/3487313-care-com-eps-beats-0_01-misses-revenue

Haemonetics EPS beats by $0.17, beats on revenue

Haemonetics (NYSE:HAE): Q1 Non-GAAP EPS of $0.81 beats by $0.17; GAAP EPS of -$0.17 misses by $0.66.

Revenue of $238.45M (+4.0% Y/Y) beats by $1.63M.

Press Release

https://seekingalpha.com/news/3487321-haemonetics-eps-beats-0_17-beats-revenue

Syneos Health EPS beats by $0.04, beats on revenue

Syneos Health (NASDAQ:SYNH): Q2 Non-GAAP EPS of $0.74 beats by $0.04; GAAP EPS of $0.11 misses by $0.10.

Revenue of $1.17B (+9.3% Y/Y) beats by $20M.

Press Release

https://seekingalpha.com/news/3487324-syneos-health-eps-beats-0_04-beats-revenue

Mallinckrodt up 12% premarket on Q2 beat, generics spin-out delayed

Mallinckrodt (MNK) Q2 results: Revenues: $823.3M (-0.3%); Specialty Brands: $627.8M (-0.6%); Specialty Generics: $195.5M (+0.9%).

Specialty Brands: Acthar Gel: $266.4M (-9.1%); Inomax: $139.7M (+6.6%); Ofirmev: $90.5M (+5.7%); Therakos: $60.9M (+7.2%); Amitiza: $52M (+8.3%); BioVectra: $13.9M (+23.0%); Other: $4.4M (-24.1%).

Net Loss: ($0.5M) (-115.6%); Loss Per Share: ($0.01) (-125.0%); Non-GAAP Net Income: $213M (+18.2%); Non-GAAP EPS: $2.53 (+17.1%); CF Ops: $467.4M (+78.5%).

Citing market conditions, it is suspending its previously announced spin-out of its generics business.

2019 Guidance: Non-GAAP EPS: $8.40 – 8.70 from $8.30 – 8.60; Sales growth for Specialty Brands segment: (5%) to 1% from 1% to 4%; Sales growth for Specialty Generics segment: Increase 2% to 5% (unch).

Update: Shares are up 12% premarket.

Previously: Mallinckrodt EPS beats by $0.45, beats on revenue (Aug. 6)

https://seekingalpha.com/news/3487330-mallinckrodt-12-percent-premarket-q2-beat-generics-spin-delayed